Prabhakar Pranav Kumar, Khurana Navneet, Vyas Manish, Sharma Vikas, Batiha Gaber El-Saber, Kaur Harpreet, Singh Jashanpreet, Kumar Deepak, Sharma Neha, Kaushik Ajeet, Kumar Raj
School of Allied Medical Sciences, Lovely Professional University, Punjab 144411, India.
School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144411, India.
Pharmaceutics. 2023 Jan 30;15(2):451. doi: 10.3390/pharmaceutics15020451.
Coronavirus, a causative agent of the common cold to a much more complicated disease such as "severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)", is a member of the coronaviridae family and contains a positive-sense single-stranded RNA of 26-32 kilobase pairs. COVID-19 has shown very high mortality and morbidity and imparted a significantly impacted socioeconomic status. There are many variants of SARS-CoV-2 that have originated from the mutation of the genetic material of the original coronavirus. This has raised the demand for efficient treatment/therapy to manage newly emerged SARS-CoV-2 infections successfully. However, different types of vaccines have been developed and administered to patients but need more attention because COVID-19 is not under complete control. In this article, currently developed nanotechnology-based vaccines are explored, such as inactivated virus vaccines, mRNA-based vaccines, DNA-based vaccines, S-protein-based vaccines, virus-vectored vaccines, etc. One of the important aspects of vaccines is their administration inside the host body wherein nanotechnology can play a very crucial role. Currently, more than 26 nanotechnology-based COVID-19 vaccine candidates are in various phases of clinical trials. Nanotechnology is one of the growing fields in drug discovery and drug delivery that can also be used for the tackling of coronavirus. Nanotechnology can be used in various ways to design and develop tools and strategies for detection, diagnosis, and therapeutic and vaccine development to protect against COVID-19. The design of instruments for speedy, precise, and sensitive diagnosis, the fabrication of potent sanitizers, the delivery of extracellular antigenic components or mRNA-based vaccines into human tissues, and the administration of antiretroviral medicines into the organism are nanotechnology-based strategies for COVID-19 management. Herein, we discuss the application of nanotechnology in COVID-19 vaccine development and the challenges and opportunities in this approach.
冠状病毒是冠状病毒科的一员,其遗传物质为26 - 32千碱基对的正链单链RNA,可引发普通感冒,也能导致更为复杂的疾病,如“严重急性呼吸综合征(SARS-CoV-2)、中东呼吸综合征(MERS-CoV-2)和2019冠状病毒病(COVID-19)”。COVID-19已显示出极高的死亡率和发病率,并对社会经济状况产生了重大影响。SARS-CoV-2有许多变种,它们源自原始冠状病毒遗传物质的突变。这就增加了对有效治疗方法的需求,以便成功应对新出现的SARS-CoV-2感染。然而,尽管已经研发出不同类型的疫苗并给患者接种,但由于COVID-19尚未得到完全控制,仍需更多关注。在本文中,我们探讨了目前基于纳米技术研发的疫苗,如灭活病毒疫苗、基于信使核糖核酸的疫苗、基于脱氧核糖核酸的疫苗、基于刺突蛋白的疫苗、病毒载体疫苗等。疫苗的一个重要方面是其在宿主体内的接种方式,而纳米技术在这方面可以发挥非常关键的作用。目前有超过26种基于纳米技术的COVID-19候选疫苗正处于临床试验的不同阶段。纳米技术是药物研发和药物递送领域中不断发展的领域之一,也可用于应对冠状病毒。纳米技术可通过多种方式用于设计和开发检测、诊断、治疗及疫苗研发的工具和策略,以预防COVID-19。用于快速、精确和灵敏诊断的仪器设计、高效消毒剂的制造、将细胞外抗原成分或基于信使核糖核酸的疫苗递送至人体组织以及将抗逆转录病毒药物施用于机体,这些都是基于纳米技术的COVID-19应对策略。在此,我们讨论纳米技术在COVID-19疫苗研发中的应用以及这种方法所面临的挑战和机遇。